RxDoctor Payments Data

Jeffery Laubenthal, MD

Family Medicine · Tuscaloosa, ALNPI 1184796211

Payments from drug & device makers

$16,448in general payments, 2019–2025

Across 1,187 payments — averaging $13.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$2K
  • Amgen$1K
  • AstraZeneca$1K
  • Pfizer$1K
  • Lilly USA, LLC$862
  • plus $9K from 54 others

What the payments were for

  • Food & beverage$16,32599%
  • Education$1231%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)149$1,574
Novo Nordisk132$1,561
Amgen86$1,269
AstraZeneca70$1,068
Pfizer65$1,011
Lilly USA, LLC60$862
Optinose US, Inc.49$724
GSK57$722
Takeda Pharmaceuticals U.S.A., Inc.35$644
Johnson & Johnson(2 entities)57$603
Amarin Pharma, Inc.44$511
Bayer28$465
Corium, LLC32$412
Antares Pharma, Inc.18$320
Eisai Inc.21$296
Merck24$289
Abbott14$277
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC18$273
OPKO Pharmaceuticals, LLC29$241
Boehringer Ingelheim17$238
Esperion Therapeutics, Inc.14$228
Biohaven Pharmaceutical Holding Company Ltd.10$214
Neos Therapeutics, LP13$204
Tris Pharma Inc7$127
Novartis8$127
Teva Pharmaceuticals USA, Inc.8$126
Sanofi-aventis U.S. LLC7$111
Aytu Biopharma, Inc.7$107
Dexcom, Inc.6$103
Otsuka America Pharmaceutical, Inc.7$101
Biohaven Pharmaceuticals, Inc.6$97
Axsome Therapeutics, Inc.4$95
Pacira Therapeutics, Inc.5$93
Jazz Pharmaceuticals Inc.5$89
Sanofi Pasteur Inc.4$84
Phathom Pharmaceuticals, Inc.8$80
Exact Sciences5$80
Ferring Pharmaceuticals Inc.2$74
Genentech USA, Inc.4$69
Kowa Pharmaceuticals America, Inc.5$69
Arbor Pharmaceuticals, Inc.4$65
Neurocrine Biosciences, Inc.3$64
Daiichi Sankyo Inc.3$61
IBSA Pharma Inc.4$61
Idorsia Pharmaceuticals US Inc4$56
Clarus Therapeutics Inc.4$54
Halozyme Inc2$54
Supernus Pharmaceuticals, Inc.2$42
Adlon Therapeutics L.p.2$34
Bioventus LLC2$32
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)2$32
Tolmar, Inc.2$32
Astellas Pharma US Inc2$31
Xeris Pharmaceuticals, Inc.1$23
Alnylam Pharmaceuticals Inc.1$21
Collegium Pharmaceutical, Inc.1$21
Ultragenyx Pharmaceutical Inc.1$20
Noven Therapeutics, LLC1$19
Ironwood Pharmaceuticals, Inc1$16
Pacira Pharmaceuticals Incorporated1$16

How this compares

$16,448 in reported general payments places this provider in the 95th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$171,502
Medicare patients
371
Services billed
7,908

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide134$145,823
MounjaroTirzepatide41$46,357
JanuviaSitagliptin Phosphate39$36,887
EliquisApixaban41$27,350
XareltoRivaroxaban26$22,601
RybelsusSemaglutide16$19,504
Repatha SureclickEvolocumab20$15,658
VascepaIcosapent Ethyl13$14,284
MyrbetriqMirabegron20$8,531
LinzessLinaclotide12$8,466
BelsomraSuvorexant14$6,219
Levothyroxine Sodium292$5,836
Gabapentin406$5,208
Atorvastatin Calcium368$4,031
Mometasone Furoate25$3,909

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,561$165,327150 claims
Lilly USA, LLCMounjaro$862$46,35741 claims
MerckJanuvia, Belsomra$289$43,10653 claims
PfizerEliquis$1,011$27,35041 claims
Johnson & JohnsonXarelto$603$22,60126 claims
AbbVieLinzess, Synthroid$1,574$10,24234 claims
Astellas Pharma US IncMyrbetriq$31$8,53120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Tuscaloosa

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →